• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations.

作者信息

Neth Bryan J, Wefel Jeffrey S, Nead Kevin T

机构信息

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Transl Androl Urol. 2025 Apr 30;14(4):864-867. doi: 10.21037/tau-2024-747. Epub 2025 Apr 15.

DOI:10.21037/tau-2024-747
PMID:40376525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12076222/
Abstract
摘要

相似文献

1
Cognitive outcomes in prostate cancer treatment: insights from the ODENZA trial and future considerations.前列腺癌治疗中的认知结果：来自ODENZA试验的见解及未来考量
Transl Androl Urol. 2025 Apr 30;14(4):864-867. doi: 10.21037/tau-2024-747. Epub 2025 Apr 15.
2
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.达洛鲁胺与恩杂鲁胺用于无症状或轻度症状性转移性去势抵抗性前列腺癌男性患者的随机、开放标签、交叉2期试验：ODENZA中的患者偏好与认知功能
Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2.
3
Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.达洛鲁胺作为第二代雄激素受体抑制剂在前列腺癌治疗中的应用
Curr Mol Med. 2021;21(4):332-346. doi: 10.2174/1566524020666200903120344.
4
The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer.第二代雄激素受体信号抑制剂在非转移性去势抵抗性前列腺癌患者中的预后优势。
Jpn J Clin Oncol. 2025 Feb 4;55(2):164-171. doi: 10.1093/jjco/hyae155.
5
Updates in the Treatment of Non-Metastatic Castrate-Resistant Prostate Cancer: The Benefit of Second-Generation Androgen Receptor Antagonists.非转移性去势抵抗性前列腺癌治疗的进展：第二代雄激素受体拮抗剂的益处
Ann Pharmacother. 2023 Nov;57(11):1302-1311. doi: 10.1177/10600280231155441. Epub 2023 Feb 24.
6
Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.第二代雄激素受体拮抗剂作为三种形式前列腺癌的激素治疗药物。
Molecules. 2020 May 24;25(10):2448. doi: 10.3390/molecules25102448.
7
Rapid Development of Spinal Epidural Lipomatosis after Treatment of Metastatic Castration-Resistant Prostate Cancer with Second-Generation Androgen Receptor Antagonists.
World Neurosurg. 2019 May;125:222-227. doi: 10.1016/j.wneu.2019.01.222. Epub 2019 Feb 11.
8
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.雄激素剥夺疗法治疗前列腺癌：关注认知功能和情绪。
Medicina (Kaunas). 2023 Dec 30;60(1):77. doi: 10.3390/medicina60010077.
9
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.第二代抗雄激素药物联合雄激素剥夺治疗联合放射治疗在高危前列腺癌的确定性治疗中的应用。
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):30-40. doi: 10.1038/s41391-022-00598-3. Epub 2022 Oct 6.
10
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges.正在研究用于治疗耐药前列腺癌的新型雄激素受体拮抗剂：进展与挑战
Expert Rev Anticancer Ther. 2025 May;25(5):457-470. doi: 10.1080/14737140.2025.2481141. Epub 2025 Mar 20.

本文引用的文献

1
Brain Metabolic Correlates of the Off-Target Effects of Enzalutamide on the Central Nervous System of Patients with Advanced Prostate Cancer.
J Nucl Med. 2024 Aug 1;65(8):1327. doi: 10.2967/jnumed.124.267526.
2
Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.前列腺癌激素疗法对认知的影响：探寻真相仍在继续。
Cancer. 2024 Jun 15;130(12):2098-2100. doi: 10.1002/cncr.35283. Epub 2024 Mar 16.
3
Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients' Real-World Insights for Optimizing Outcomes.前列腺癌患者与治疗相关的认知障碍：患者对优化治疗结果的真实见解
Adv Ther. 2024 Feb;41(2):476-491. doi: 10.1007/s12325-023-02721-9. Epub 2023 Nov 18.
4
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.《前列腺癌（第四版）》，2023 年，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050.
5
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.达洛鲁胺与恩杂鲁胺用于无症状或轻度症状性转移性去势抵抗性前列腺癌男性患者的随机、开放标签、交叉2期试验：ODENZA中的患者偏好与认知功能
Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2.
6
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis.第二代抗雄激素与随机临床试验中认知和功能毒性作用的关联：系统评价和荟萃分析。
JAMA Oncol. 2023 Jul 1;9(7):930-937. doi: 10.1001/jamaoncol.2023.0998.
7
Second generation androgen receptor antagonists and challenges in prostate cancer treatment.第二代雄激素受体拮抗剂及其在前列腺癌治疗中的挑战。
Cell Death Dis. 2022 Jul 21;13(7):632. doi: 10.1038/s41419-022-05084-1.
8
Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.雄激素剥夺疗法对前列腺癌男性认知功能的影响：系统评价。
Int J Urol. 2021 Aug;28(8):786-798. doi: 10.1111/iju.14596. Epub 2021 Jun 14.
9
Hormonal Therapy for Prostate Cancer.前列腺癌的激素治疗。
Endocr Rev. 2021 May 25;42(3):354-373. doi: 10.1210/endrev/bnab002.
10
Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review.雄激素受体轴靶向药物对前列腺癌男性认知和抑郁的影响：系统评价。
J Geriatr Oncol. 2021 Jun;12(5):687-695. doi: 10.1016/j.jgo.2020.11.002. Epub 2020 Nov 22.